Pfizer Expands Cancer Pipeline Through Strategic Partnership With Innovent Biologics
Pfizer Inc. (NYSE:PFE) has entered into a global strategic licensing and collaboration agreement with Innovent Biologics to jointly develop 12 early-stage oncology programs, including antibody-drug conjugates and multi-specific antibodies. The partnership includes an upfront payment of $650 million for Innovent and potential milestone payments totaling up to $9.85 billion.
Tickers: $PFE
Topics: Innovent Biologics oncology pipeline expansion Pfizer Phase 2 vaccine trial